Randomized, double-blind phase III study of pazopanib in patients with advanced/metastatic renal cell carcinoma (mRCC): Final overall survival (OS) results - Sternberg, C N; Hawkins, R E; Szczylik, C (Ann Oncol, 2010)
viii10 (ESMO 2010, Abstr. #LBA22)